Targeting USP24 by USP24-i-101 induces autophagy in interphase and mitosis by inhibiting E2F4 and TRAF6, respectively, thereby inhibiting the expression of ABCG2 and PD-L1 and maintaining genomic integrity, resulting in the inhibition of drug resistance acquired by gefitinib- or Taxol-treatment of lung cancer (Fig. 8D). Here, ABCG2 is linked to lung carcinoma.